Small-molecule inhibitors of Wnt signaling pathway: towards novel anticancer therapeutics

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Nusse R, Varmus HE. Wnt genes. Cell 69(7), 1073–1087 (1992).
  Medline CASGoogle Scholar
• 2 Stewart DJ. Wnt signaling pathway in non–small cell lung cancer. J. Natl Cancer Inst 106(1), djt356 (2014).
  MedlineGoogle Scholar
• 3 Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu. Rev. Cell Dev. Biol. 20, 781–810 (2004).
  Medline CASGoogle Scholar
• 4 Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell 149(6), 1192–1205 (2012).
  Medline CASGoogle Scholar
• 5 Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat. Rev. Cancer 13(1), 11–26 (2012).
  Google Scholar
• 6 Polakis P. Wnt signaling in cancer. Cold Spring Harb. Perspect. Biol 4(5), a008052 (2012).
  MedlineGoogle Scholar
• 7 Wu Y, Ginther C, Kim J et al. Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells. Mol. Cancer Res. 10(12), 1597–1606 (2012).
  Medline CASGoogle Scholar
• 8 NIH National Cancer Institute. Combination chemotherapy and bevacizumab with or without PRI-724 in treating patients with newly diagnosed metastatic colorectal cancer. www.cancer.gov/about-cancer/treatment/clinical-trials/search/view?cdrid=771168&version=HealthProfessional&protocolsearchid=9920214.
  Google Scholar
• 9 Van Es JH, Clevers H. Notch and Wnt inhibitors as potential new drugs for intestinal neoplastic disease. Trends Mol. Med. 11(11), 496–502 (2005).
  Medline CASGoogle Scholar
• 10 Voronkov A, Krauss S. Wnt/beta-catenin signaling and small molecule inhibitors. Curr. Pharm. Des 19(4), 634 (2012).
  Google Scholar
• 11 Le PN, Mcdermott JD, Jimeno A. Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54F28. Pharmacol. Ther. 146(0), 1–11 (2015).
  Medline CASGoogle Scholar
• 12 Kahn M. Can we safely target the WNT pathway?. Nat. Rev. Drug Discov. 13(7), 513–532 (2014).
  Medline CASGoogle Scholar
• 13 Lee H-J, Zhang X, Zheng JJ. Inhibiting the Wnt signaling pathway with small molecules. In: Targeting the Wnt Pathway in Cancer. Gross KH, Khan M (Eds). Springer, NY, USA, 183–209 (2011).
  Google Scholar
• 14 Chen Z, Li J, Li QS et al. Suppression of PPN/MG61 attenuates Wnt/[beta]-catenin signaling pathway and induces apoptosis in human lung cancer. Oncogene 27(24), 3483–3488 (2008).
  Medline CASGoogle Scholar
• 15 Chen B, Dodge ME, Tang W et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat. Chem. Biol. 5(2), 100–107 (2009). • First report on the small-molecule inhibitor of porcupine.
  Medline CASGoogle Scholar
• 16 Dodge ME, Moon J, Tuladhar R et al. Diverse chemical scaffolds support direct inhibition of the membrane-bound O-acyltransferase porcupine. J. Biol. Chem. 287(27), 23246–23254 (2012).
  Medline CASGoogle Scholar
• 17 Wang X, Moon J, Dodge ME et al. The development of highly potent inhibitors for Porcupine. J. Med. Chem. 56(6), 2700–2704 (2013).
  Medline CASGoogle Scholar
• 18 Liu J, Pan S, Hsieh MH et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc. Natl Acad. Sci. USA 110(50), 20224–20229 (2013). • Development of one of two small-molecule inhibitors of Wnt signaling pathways that are in clinical trials.
  Medline CASGoogle Scholar
• 19 Proffitt KD, Madan B, Ke Z et al. Pharmacological inhibition of the Wnt acyltransferase PORCN prevents growth of WNT-driven mammary cancer. Cancer Res. 73(2), 502–507 (2013).
  Medline CASGoogle Scholar
• 20 Duraiswamy AJ, Lee MA, Madan B et al. Discovery and optimization of a porcupine inhibitor. J. Med. Chem. 58(15), 5889–5899 (2015).
  Medline CASGoogle Scholar
• 21 Riffell JL, Lord CJ, Ashworth A. Tankyrase-targeted therapeutics: expanding opportunities in the PARP family. Nat. Rev. Drug Discov. 11(12), 923–936 (2012).
  Medline CASGoogle Scholar
• 22 Huang S-MA, Mishina YM, Liu S. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461(7264), 614–620 (2009). • Discovered the first tankyrase inhibitor.
  Medline CASGoogle Scholar
• 23 Karlberg T, Markova N, Johansson I et al. Structural basis for the interaction between tankyrase-2 and a potent Wnt-signaling inhibitor. J. Med. Chem. 53(14), 5352–5355 (2010).
  Medline CASGoogle Scholar
• 24 Nathubhai A, Wood PJ, Lloyd MD, Thompson AS, Threadgill MD. Design and discovery of 2-arylquinazolin-4-ones as potent and selective inhibitors of tankyrases. ACS Med. Chem. Lett. 4(12), 1173–1177 (2013).
  Medline CASGoogle Scholar
• 25 Haikarainen T, Koivunen J, Narwal M et al. Para-substituted 2-phenyl-3,4-dihydroquinazolin-4-ones as potent and selective tankyrase inhibitors. ChemMedChem 8(12), 1978–1985 (2013).
  Medline CASGoogle Scholar
• 26 Johannes JW, Almeida L, Barlaam B et al. Pyrimidinone nicotinamide mimetics as selective tankyrase and Wnt pathway inhibitors suitable for in vivo pharmacology. ACS Med. Chem. Lett. 6(3), 254–259 (2015).
  Medline CASGoogle Scholar
• 27 Shultz MD, Majumdar D, Chin DN et al. Structure–efficiency relationship of [1,2,4]Triazol-3-ylamines as novel nicotinamide isosteres that inhibit tankyrases. J. Med. Chem. 56(17), 7049–7059 (2013).
  Medline CASGoogle Scholar
• 28 Kirby CA, Cheung A, Fazal A, Shultz MD, Stams T. Structure of human tankyrase 1 in complex with small-molecule inhibitors PJ34 and XAV939. Acta Crystallographica Section F 68(Pt 2), 115–118 (2012).
  CASGoogle Scholar
• 29 Liscio P, Carotti A, Asciutti S et al. Design, synthesis, crystallographic studies, and preliminary biological appraisal of new substituted triazolo[4,3-b]pyridazin-8-amine derivatives as tankyrase inhibitors. J. Med. Chem. 57(6), 2807–2812 (2014).
  Medline CASGoogle Scholar
• 30 Larsson EA, Jansson A, Ng FM et al. Fragment-based ligand design of novel potent inhibitors of tankyrases. J. Med. Chem. 56(11), 4497–4508 (2013).
  Medline CASGoogle Scholar
• 31 Liscio P, Carotti A, Asciutti S et al. Scaffold hopping approach on the route to selective tankyrase inhibitors. Eur. J. Med. Chem. 87(0), 611–623 (2014).
  Medline CASGoogle Scholar
• 32 Narwal M, Haikarainen T, Fallarero A, Vuorela PM, Lehtiö L. Screening and structural analysis of flavones inhibiting tankyrases. J. Med. Chem. 56(9), 3507–3517 (2013).
  Medline CASGoogle Scholar
• 33 Narwal M, Venkannagari H, Lehtiö L. Structural basis of selective inhibition of human tankyrases. J. Med. Chem. 55(3), 1360–1367 (2012). • Discovery of non-nicotinamide-binding site for tankyrase inhibitors
  Medline CASGoogle Scholar
• 34 Lu J, Ma Z, Hsieh J-C et al. Structure–activity relationship studies of small-molecule inhibitors of Wnt response. Bioorg. Med. Chem. Lett. 19(14), 3825–3827 (2009).
  Medline CASGoogle Scholar
• 35 Lanier M, Schade D, Willems E et al. Wnt inhibition correlates with human embryonic stem cell cardiomyogenesis: a structure–activity relationship study based on inhibitors for the Wnt response. J. Med. Chem. 55(2), 697–708 (2012).
  Medline CASGoogle Scholar
• 36 Bregman H, Chakka N, Guzman-Perez A et al. Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors. J. Med. Chem. 56(11), 4320–4342 (2013).
  Medline CASGoogle Scholar
• 37 Huang H, Guzman-Perez A, Acquaviva L et al. Structure-based design of 2-aminopyridine oxazolidinones as potent and selective tankyrase inhibitors. ACS Med. Chem. Lett. 4(12), 1218–1223 (2013).
  Medline CASGoogle Scholar
• 38 James RG, Davidson KC, Bosch KA et al. WIKI4, a novel inhibitor of tankyrase and Wnt/ss-catenin signaling. PLoS ONE 7(12), e50457 (2012).
  Medline CASGoogle Scholar
• 39 Haikarainen T, Venkannagari H, Narwal M et al. Structural basis and selectivity of tankyrase inhibition by a Wnt signaling inhibitor WIKI4. PLoS ONE 8(6), e65404 (2013).
  Medline CASGoogle Scholar
• 40 Waaler J, Machon O, Von Kries JP et al. Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth. Cancer Res. 71(1), 197–205 (2011).
  Medline CASGoogle Scholar
• 41 Wessel Stratford E, Daffinrud J, Munthe E et al. The tankyrase-specific inhibitor JW74 affects cell cycle progression and induces apoptosis and differentiation in osteosarcoma cell lines. Cancer Med. 3(1), 36–46 (2014).
  Medline CASGoogle Scholar
• 42 Shultz MD, Kirby CA, Stams T et al. [1,2,4]Triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding. J. Med. Chem. 55(3), 1127–1136 (2012).
  Medline CASGoogle Scholar
• 43 Waaler J, Machon O, Tumova L et al. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. Cancer Res. 72(11), 2822–2832 (2012).
  Medline CASGoogle Scholar
• 44 Voronkov A, Holsworth DD, Waaler J et al. Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor. J. Med. Chem. 56(7), 3012–3023 (2013).
  Medline CASGoogle Scholar
• 45 Lau T, Chan E, Callow M et al. A novel tankyrase small-molecule inhibitor suppresses APC mutation–driven colorectal tumor growth. Cancer Res. 73(10), 3132–3144 (2013).
  Medline CASGoogle Scholar
• 46 Kirubakaran P, Arunkumar P, Premkumar K, Muthusamy K. Sighting of tankyrase inhibitors by structure- and ligand-based screening and in vitro approach. Mol. Biosyst. 10(10), 2699–2712 (2014).
  Medline CASGoogle Scholar
• 47 Bregman H, Gunaydin H, Gu Y et al. Discovery of a class of novel tankyrase inhibitors that bind to both the nicotinamide pocket and the induced pocket. J. Med. Chem. 56(3), 1341–1345 (2013).
  Medline CASGoogle Scholar
• 48 Hua Z, Bregman H, Buchanan JL et al. Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors. J. Med. Chem. 56(24), 10003–10015 (2013).
  Medline CASGoogle Scholar
• 49 Shultz MD, Cheung AK, Kirby CA et al. Identification of NVP-TNKS656: the use of structure–efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitor. J. Med. Chem. 56(16), 6495–6511 (2013).
  Medline CASGoogle Scholar
• 50 Hao J, Ao A, Zhou L et al. Selective small molecule targeting β-catenin function discovered by in vivo chemical genetic screen. Cell Rep. 4(5), 898–904 (2013).
  Medline CASGoogle Scholar
• 51 Ashihara E, Kawata E, Nakagawa Y et al. β-catenin small interfering RNA successfully suppressed progression of multiple myeloma in a mouse model. Clin. Cancer. Res. 15(8), 2731–2738 (2009).
  Medline CASGoogle Scholar
• 52 Scholer-Dahirel A, Schlabach MR, Loo A et al. Maintenance of adenomatous polyposis coli (APC)-mutant colorectal cancer is dependent on Wnt/β-catenin signaling. Proc. Natl Acad. Sci. USA 108(41), 17135–17140 (2011).
  Medline CASGoogle Scholar
• 53 Lepourcelet M, Chen Y-NP, France DS et al. Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex. Cancer Cell 5(1), 91–102 (2004). • Identified the inhibitors of β-catenin/T-cell factor interaction.
  Medline CASGoogle Scholar
• 54 Lee M-A, Kim WK, Park HJ, Kang SS, Lee SK. Anti-proliferative activity of hydnocarpin, a natural lignan, is associated with the suppression of Wnt/β-catenin signaling pathway in colon cancer cells. Bioorg. Med. Chem. Lett. 23(20), 5511–5514 (2013).
  Medline CASGoogle Scholar
• 55 Chen Z, Venkatesan AM, Dehnhardt CM et al. 2,4-Diamino-quinazolines as inhibitors of β-catenin/Tcf-4 pathway: Potential treatment for colorectal cancer. Bioorg. Med. Chem. Lett. 19(17), 4980–4983 (2009).
  Medline CASGoogle Scholar
• 56 Park CH, Chang JY, Hahm ER, Park S, Kim H-K, Yang CH. Quercetin, a potent inhibitor against β-catenin/Tcf signaling in SW480 colon cancer cells. Biochem. Biophys. Res. Commun. 328(1), 227–234 (2005).
  Medline CASGoogle Scholar
• 57 Yu B, Huang Z, Zhang M, Dillard DR, Ji H. Rational design of small-molecule inhibitors for β-catenin/T-cell factor protein–protein interactions by bioisostere replacement. ACS Chem. Biol. 8(3), 524–529 (2013).
  Medline CASGoogle Scholar
• 58 Zhang M, Catrow JL, Ji H. High-throughput selectivity assays for small-molecule inhibitors of β-catenin/T-cell factor protein–protein interactions. ACS Med. Chem. Lett. 4(2), 306–311 (2013).
  Medline CASGoogle Scholar
• 59 Catrow JL, Zhang Y, Zhang M, Ji H. Discovery of selective small-molecule inhibitors for the β-Catenin/T-Cell factor protein–protein interaction through the optimization of the acyl hydrazone moiety. J. Med. Chem. 58(11), 4678–4692 (2015).
  Medline CASGoogle Scholar
• 60 Lu D, Liu JX, Endo T et al. Ethacrynic acid exhibits selective toxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt/β-catenin pathway. PLoS ONE 4(12), e8294 (2009).
  MedlineGoogle Scholar
• 61 Wall I, Schmidt-Wolf IGH. Effect of Wnt inhibitors in pancreatic cancer. Anticancer Res. 34(10), 5375–5380 (2014).
  Medline CASGoogle Scholar
• 62 Emami KH, Nguyen C, Ma H et al. A small molecule inhibitor of β-catenin/cyclic AMP response element-binding protein transcription. Proc. Natl Acad. Sci. USA 101(34), 12682–12687 (2004). • Identified a specific inhibitor of binding cyclic AMP response element-binding protein, which is also in clinical trial.
  Medline CASGoogle Scholar
• 63 Jin G, Lu D, Yao S et al. Amide derivatives of ethacrynic acid: synthesis and evaluation as antagonists of Wnt/β-catenin signaling and CLL cell survival. Bioorg. Med. Chem. Lett. 19(3), 606–609 (2009).
  Medline CASGoogle Scholar
• 64 Arensman MD, Telesca D, Lay AR et al. The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer growth.Mol. Cancer Ther. 13(10), 2303–2314 (2014).
  CASGoogle Scholar
• 65 Gonsalves FC, Klein K, Carson BB et al. An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway. Proc. Natl Acad. Sci. USA 108(15), 5954–5963 (2011).
  Medline CASGoogle Scholar
• 66 Bilir B, Kucuk O, Moreno CS. Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells. J. Transl. Med 11(1), 280 (2013).
  MedlineGoogle Scholar
• 67 Zhang W, Sviripa V, Kril LM et al. Fluorinated N,N-Dialkylaminostilbenes for Wnt Pathway Inhibition and Colon Cancer Repression. J. Med. Chem. 54(5), 1288–1297 (2011).
  Medline CASGoogle Scholar
• 68 Schmeel FC, Schmeel LC, Kim Y, Schmidt-Wolf IG. Piceatannol exhibits selective toxicity to multiple myeloma cells and influences the Wnt/beta-catenin pathway. Hematol. Oncol. 32(4), 197–204 (2014).
  Medline CASGoogle Scholar
• 69 Albring KF, Weidemüller J, Mittag S et al. Berberine acts as a natural inhibitor of Wnt/β-catenin signaling-Identification of more active 13-arylalkyl derivatives. Biofactors 39(6), 652–662 (2013).
  Medline CASGoogle Scholar
• 70 Chen M, Wang J, Lu J et al. The anti-helminthic niclosamide inhibits Wnt/frizzled1 signaling. Biochemistry 48(43), 10267–10274 (2009).
  Medline CASGoogle Scholar
• 71 Gödeke J, Maier S, Eichenmüller M, Müller-Höcker J, Von Schweinitz D, Kappler R. Epigallocatechin-3-gallate inhibits hepatoblastoma growth by reactivating the Wnt inhibitor SFRP1. Nutr. Cancer 65(8), 1200–1207 (2013).
  MedlineGoogle Scholar
• 72 Aguilera O, Peña C, García JM et al. The Wnt antagonist DICKKOPF-1 gene is induced by 1α, 25-dihydroxyvitamin D3 associated to the differentiation of human colon cancer cells. Carcinogenesis 28(9), 1877–1884 (2007).
  Medline CASGoogle Scholar
• 73 Gustafson B, Eliasson B, Smith U. Thiazolidinediones increase the wingless-type MMTV integration site family (WNT) inhibitor Dickkopf-1 in adipocytes: a link with osteogenesis. Diabetologia 53(3), 536–540 (2010).
  Medline CASGoogle Scholar
• 74 Gilbert AM, Bursavich MG, Alon N et al. Hit to lead studies on (hetero)arylpyrimidines – agonists of the canonical Wnt-β-catenin cellular messaging system. Bioorg. Med. Chem. Lett. 20(1), 366–370 (2010).
  Medline CASGoogle Scholar
• 75 Shan J, Shi D-L, Wang J, Zheng J. Identification of a specific inhibitor of the dishevelled PDZ domain. Biochemistry 44(47), 15495–15503 (2005).
  Medline CASGoogle Scholar
• 76 Fujii N, You L, Xu Z et al. An antagonist of dishevelled protein-protein interaction suppresses β-catenin-dependent tumor cell growth. Cancer Res. 67(2), 573–579 (2007).
  Medline CASGoogle Scholar
• 77 Grandy D, Shan J, Zhang X et al. Discovery and characterization of a small molecule inhibitor of the PDZ domain of dishevelled. J. Biol. Chem. 284(24), 16256–16263 (2009).
  Medline CASGoogle Scholar
• 78 Thorne CA, Hanson AJ, Schneider J et al. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α. Nat. Chem. Biol. 6(11), 829–836 (2010). • Identified a potent inhibitor of Wnt signaling by activating casein kinase 1-α.
  Medline CASGoogle Scholar
• 79 De Robertis A, Valensin S, Rossi M et al. Identification and characterization of a small-molecule inhibitor of Wnt signaling in glioblastoma cells. Mol. Cancer Ther. 12(7), 1180–1189 (2013).
  Medline CASGoogle Scholar
• 80 De Robertis A, Mennillo F, Rossi M et al. Human sarcoma growth is sensitive to small-molecule mediated AXIN stabilization. PLoS ONE 9(5), e97847 (2014).
  MedlineGoogle Scholar
• 81 Zhang J, Kong L-M, Zhan R et al. Two natural ent-kauranoids as novel Wnt signaling inhibitors. Nat. Prod. Bioprospect. 4(3), 135–140 (2014).
  Medline CASGoogle Scholar
• 82 Koval AV, Vlasov P, Shichkova P et al. Anti-leprosy drug clofazimine inhibits growth of triple-negative breast cancer cells via inhibition of canonical Wnt signaling. Biochem. Pharmacol. 87(4), 571–578 (2014).
  Medline CASGoogle Scholar
• 83 Soldi R, Horrigan SK, Cholody MW et al. Design, synthesis, and biological evaluation of a series of anthracene-9,10-dione dioxime β-catenin pathway inhibitors. J. Med. Chem. 58(15), 5854–5862 (2015).
  Medline CASGoogle Scholar
• 84 De Vicente J, Tivitmahaisoon P, Berry P et al. Fragment-based drug design of novel pyranopyridones as cell active and orally bioavailable tankyrase inhibitors. ACS Med. Chem. Lett. 6(9), 1019–1024 (2015).
  Medline CASGoogle Scholar
• 85 Higuchi Y, Nguyen C, Yasuda S-Y, Mcmillan M, Hasegawa K, Kahn M. Specific direct small molecule p300/β-catenin antagonists maintain stem cell potency. Curr. Mol. Pharmacol. 8, 1–8 (2015).
  Google Scholar
• 86 Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic [bgr]-catenin signalling prevents anti-tumour immunity. Nature 523(7559), 231–235 (2015). •• Revealed a correlation between activation of Wnt/β-catenin signaling pathway and absence of a T-cell gene expression signature.
  Medline CASGoogle Scholar